Absorption of myo-inositol hexakisphosphate (InsP6) through the skin in humans

Pharmazie

Volumn 61, Issue 7, 2006, Pages 652-

  Grases, F ^a   Isern, B ^a   Perello J ^a   Sanchis, P ^a   Prieto, R M ^a   Costa Bauza A ^a  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MYO INOSITOL HEXAKIPHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG DELIVERY SYSTEM; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN;

ADMINISTRATION, TOPICAL; ADULT; DIET; FEMALE; HUMANS; MALE; PHYTIC ACID; SKIN ABSORPTION;

EID: 33746227647     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Bode AM, Dong Z (2000) Signal transduction pathways: targets for chemoprevention of skin cancer. Lancet Oncol 1: 181-188.
2. Grases F, Perelló J, Isern B, Prieto RM (2005) Study of a myo-inositol hexaphosphate-based cream to prevent dystrophic calcinosis cutis. Br J Dermatol 152: 1022-1025.
3. 6) through the skin: study of the matrix effects. Mechanism of phytate topical absorption. Front Biosci 10: 799-802.
4. 6 or phytate) in humans. BioFactors 15: 53-61.
5. Gupta KP, Singh J, Bharathi R (2003) Suppression of DMBA-induced mouse skin tumor development by inositol hexaphosphate and its mode of action. Nutr Cancer 46: 66-72.
6. 6 in vivo: initiation-promotion model. Anticancer Res 19: 3749-3752.